Stay updated with breaking news from Oche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Discover the 25 Richest Families in the World according to Bloomberg's annual ranking. Learn about the Boehringer and Roche families, who have amassed their wea
ZURICH (Reuters) -Roche agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly. On top of the upfront purchase price of $2.7 billion, Carmot's equity holders will receive payments of up to $400 million if certain milestones are achieved, the Swiss drugmaker said in a statement on Monday. The takeover target's most promising drug candidate CT-388 belongs to a class known as a dual GLP-1/GIP receptor agonist, the same as Lilly's M...
Hsbc Holdings PLC increased its position in Chemed Co. (NYSE:CHE – Free Report) by 35.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,294 shares of the company’s stock after acquiring an additional 1,388 shares during the period. Hsbc […]
Roche’s Carmot Therapeutics acquisition brings three clinical-stage assets that the companies say could be best-in-class drugs for metabolic disorders. In addition to standalone use, Roche sees the Carmot molecules as part of potential combinations with its own drug candidates.
Although predictive tools to identify those at risk of disease progression are in their infancy, the development of such tools is crucial for improving patient outcomes.